cenerimod

First use of cenerimod, a selective S1P₁ receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
Viktoria Hermann, Anastas Batalov, Svetlana Smakotina, Pierre-Eric Juif, Peter Cornelisse

Lupus Science & Medicine Oct 2019, 6 (1) e000354; DOI: 10.1136/lupus-2019-000354
LSO-092 Safety, efficacy and pharmacodynamics of cenerimod in patients with systemic lupus erythematosus: two randomised, double-blind phase 2 clinical trials
Sandra V Navarra, Peter Cornelisse, Clélia Cahuzac, Yoshinari Yokoyama, Osamu Togo, Ouali Berkani

Lupus Science & Medicine Jul 2023, 10 (Suppl 1) A93; DOI: 10.1136/lupus-2023-KCR.133
LO-016 The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three key aspects of SLE pathogenesis
Thomas F Hoyler, Daniel S Strasser, Ouali Berkani, Clelia Cahuzac, Peter Cornelisse, Mark J Murphy, Marianne M Martinic

Lupus Science & Medicine Jul 2023, 10 (Suppl 1) A13-A14; DOI: 10.1136/lupus-2023-KCR.16

Main menu